Home » Stocks » MYOV

Myovant Sciences Ltd. (MYOV)

Stock Price: $19.98 USD 0.88 (4.61%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 1.75B
Revenue (ttm) 67.05M
Net Income (ttm) -283.93M
Shares Out 91.48M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $19.98
Previous Close $19.10
Change ($) 0.88
Change (%) 4.61%
Day's Open 19.40
Day's Range 18.66 - 20.10
Day's Volume 1,152,543
52-Week Range 13.42 - 30.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -219.05% and -32.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

Shares of Myovant Sciences (NYSE:MYOV) rose 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 81.08% year over year to ($0.67), which misse...

1 day ago - Benzinga

BASEL, Switzerland, July 28, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financia...

1 day ago - GlobeNewsWire

Myovant Sciences (MYOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE: MYOV) Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe symptoms...

1 week ago - Benzinga

BASEL, Switzerland, July 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Commission (EC) h...

1 week ago - GlobeNewsWire

BASEL, Switzerland, July 14, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and con...

2 weeks ago - GlobeNewsWire

Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.

Other stocks mentioned: BAYRY, BNTX, GSK, LLY, PFE
4 weeks ago - Zacks Investment Research

This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. The post 3 Biotech Stocks Ready for Big Breakthroughs Like Biogen a...

Other stocks mentioned: BPMC, PRVB
1 month ago - InvestorPlace

A lesser-known British biotech is among eight pharma companies the publication Kiplinger encouraged readers to monitor for important key clinical trial results or regulatory approvals.

1 month ago - GuruFocus

BASEL, Switzerland, June 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to li...

1 month ago - GlobeNewsWire

The FDA has approved Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc's (NYSE: PFE) relugolix combined with estradiol and norethindrone acetate for heavy menstrual bleeding linked to uterine fibroids in...

Other stocks mentioned: PFE
2 months ago - Benzinga

BASEL, Switzerland and NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

2 months ago - GlobeNewsWire

LONDON and NEW YORK, May 26, 2021 /PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant)  and...

2 months ago - PRNewsWire

European Medicines Agency's advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltd's (NYSE: MYOV) Ryeqo (relugolix, estradiol, and norethindrone acetate) for uter...

2 months ago - Benzinga

BASEL, Switzerland, May 21, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted ...

2 months ago - GlobeNewsWire

Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.

Other stocks mentioned: ALKS, BIIB, BMY, BPMC, PRVB, SNY, VRTX
2 months ago - Kiplinger

Myovant Sciences Ltd (NYSE: MYOV) has received a partial clinical hold on its SERENE study (MVT-601-050) from the FDA. The Phase 3 study was evaluating relugolix combination tablets for the prevention o...

2 months ago - Benzinga

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 10.10% and 1.17%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Myovant Sciences (NYSE:MYOV) moved higher by 4.5% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 21.92% over the past year to ($0.8...

2 months ago - Benzinga

BASEL, Switzerland, May 11, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial...

2 months ago - GlobeNewsWire

Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.

Other stocks mentioned: CPRX, HRMY, PRTA
2 months ago - Zacks Investment Research

BASEL, Switzerland, May 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conf...

2 months ago - GlobeNewsWire

Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.

Other stocks mentioned: PFE
3 months ago - Zacks Investment Research

BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SER...

3 months ago - GlobeNewsWire

BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Mer...

3 months ago - GlobeNewsWire

BASEL, Switzerland, March 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines Agency...

4 months ago - GlobeNewsWire

Myovant (MYOV) and partner Pfizer report positive data from the phase III LIBERTY study evaluating relugolix combination therapy for treating women with uterine fibroids.

4 months ago - Zacks Investment Research

Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc (NYSE: PFE) have announced positive data from the Phase 3 LIBERTY randomized withdrawal study evaluating relugolix combination therapy in women with uter...

Other stocks mentioned: PFE
4 months ago - Benzinga

BASEL, Switzerland and NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced positive data from the Phase 3 LIBERTY randomized withdrawal...

4 months ago - GlobeNewsWire

BASEL, Switzerland, March 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the four recipients of its Fo...

4 months ago - GlobeNewsWire

BASEL, Switzerland, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to li...

5 months ago - GlobeNewsWire

•LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline •Achieved six of seven key secondary endpoints including reduct...

5 months ago - GlobeNewsWire

BASEL, Switzerland and NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced publication in the New England Journal of Medicine  of the Ph...

5 months ago - GlobeNewsWire

BASEL, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards...

5 months ago - GlobeNewsWire

RED BANK, N.J. and BASEL, Switzerland, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HealthyWomen, the nation's leading independent, nonprofit health information source for women, and Myovant Sciences (NYSE: MYOV),...

5 months ago - GlobeNewsWire

Shares of Myovant Sciences (NYSE:MYOV) moved higher by 0.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 9.89% year over year to ($0.82), whi...

5 months ago - Benzinga

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 7.87% and 27.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

BASEL, Switzerland, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financia...

5 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and con...

6 months ago - GlobeNewsWire

•84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year•Data to be included in New Drug Application submission to U...

6 months ago - GlobeNewsWire

BASEL, Switzerland and NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 SPIRIT long-term extension study of the inve...

6 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards...

6 months ago - GlobeNewsWire

Over halfway through the trading day on Wednesday, and the broad markets are making a run into the afternoon.

Other stocks mentioned: TSLA, AMRS, C, GS, JPM, KDP, MDB ...
6 months ago - 24/7 Wall Street

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the release, ...

6 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief execut...

6 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix), the...

6 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV),  announced today that Myovant Sciences, a healthcare company ...

6 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David Marek...

6 months ago - GlobeNewsWire

Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.

Other stocks mentioned: PFE
7 months ago - Zacks Investment Research

About MYOV

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 27, 2016
Stock Exchange
NYSE
Ticker Symbol
MYOV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for MYOV stock is "Buy." The 12-month stock price forecast is 36.20, which is an increase of 81.18% from the latest price.

Price Target
$36.20
(81.18% upside)
Analyst Consensus: Buy